Age-related nigral downregulation of the Parkinson's risk factor FAM49B primes human microglia for inflammaging

Jacqueline Martin1,2, Guan-Ju Lai1,2,3, Christopher Y Park4

  • 1Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY, USA.

Npj Aging
|December 19, 2025
PubMed

Insights

The Parkinson's Disease (PD) risk gene FAM49B is crucial for microglial function and is downregulated with age and PD. Its loss impairs cellular functions, increasing neuroinflammation and susceptibility to PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Parkinson's Disease (PD) involves dopaminergic neuron loss in the substantia nigra pars compacta (SNpc).
  • Neuroinflammation and microglial dysfunction are implicated in PD pathogenesis.
  • The role of specific genes, like FAM49B, in microglial function and PD risk is not fully understood.

Purpose of the Study:

  • To investigate the role of the Parkinson's Disease risk gene FAM49B in microglial function.
  • To determine how FAM49B expression changes with age and in PD.
  • To elucidate the mechanism by which FAM49B influences neuroinflammation.

Main Methods:

  • Utilized human and murine microglia cell models.
  • Assessed FAM49B expression in human SNpc tissue from aging and PD individuals.
  • Analyzed the impact of FAM49B downregulation on microglial functions including cytoskeletal maintenance, migration, energy homeostasis, and inflammatory response.

Main Results:

  • FAM49B is critically expressed in human SNpc microglia and downregulated with age and PD.
  • FAM49B regulates essential microglial functions: cytoskeletal integrity, migration, adherence, energy metabolism, and autophagy.
  • Downregulation of FAM49B leads to altered microglial functions and increased activation, contributing to neuroinflammation.

Conclusions:

  • FAM49B plays a novel, cell-type-specific role in microglial function.
  • Reduced FAM49B expression presents a potential mechanism for age- and PD-associated neuroinflammation and reactive gliosis.
  • FAM49B emerges as a potential therapeutic target for mitigating neuroinflammation in Parkinson's Disease and aging.